Showing results (421-430 of 696) with videos related to
Sort By:
Pageof 70
Psychotherapy (Chicago, Ill.)|August 4, 2025
Is employment status associated with baseline symptoms, engagement, and outcomes in naturalistic psychotherapy? Evaluation in a large community mental health agencyZishan Jiwani, Qiang Xie, John J Curtin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.Seminars in Oncology|December 11, 1992
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?M Markman, T Hakes, B Reichman, et al.Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyM Markman, L C DeMarco, M Birkhofer, et al.Gynecologic Oncology|July 1, 1993
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2016
Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to RucaparibAiste McCormick, Peter Donoghue, Michelle Dixon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyM Markman, E Rowinsky, T Hakes, et al.Pageof 70